ResMed COO Robert Andrew Douglas Unloads 8,000 Shares (RMD)
ResMed (NYSE:RMD) COO Robert Andrew Douglas unloaded 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $53.20, for a total transaction of $425,600.00. Following the sale, the chief operating officer now directly owns 123,392 shares of the company’s stock, valued at approximately $6,564,454. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
ResMed (NYSE:RMD) traded up 1.20% on Friday, hitting $54.01. The stock had a trading volume of 783,853 shares. ResMed has a 52 week low of $38.08 and a 52 week high of $54.39. The stock has a 50-day moving average of $51.12 and a 200-day moving average of $47.95. The company has a market cap of $7.672 billion and a price-to-earnings ratio of 25.41.
ResMed (NYSE:RMD) last released its earnings data on Thursday, August 1st. The company reported $0.62 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.62. The company had revenue of $414.60 million for the quarter, compared to the consensus estimate of $410.89 million. During the same quarter in the previous year, the company posted $0.53 earnings per share. The company’s revenue for the quarter was up 11.5% on a year-over-year basis.
A number of research firms have recently commented on RMD. Analysts at Zacks upgraded shares of ResMed (NYSE:RMD) from a “neutral” rating to an “outperform” rating in a research note to investors on Friday. They now have a $55.40 price target on the stock. Separately, analysts at UBS AG downgraded shares of ResMed (NYSE:RMD) from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday. They now have a $50.50 price target on the stock. They noted that the move was a valuation call. Finally, analysts at Goldman Sachs Group Inc. upgraded shares of ResMed (NYSE:RMD) to a “buy” rating in a research note to investors on Monday, September 23rd. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $48.41.
ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.